Cargando…

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition

The objective was to correlate CD47 gene expression with resistance to immune checkpoint inhibitors (ICI) in tumor tissue of gynecological cancer (GC). Further, we sought to assess the efficacy of targeting CD47 pathway alone and in combination in pre-clinical ovarian cancer (OC) models. We performe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Sudani, Hussein, Ni, Ying, Jones, Philip, Karakilic, Huseyin, Cui, Lei, Johnson, Lisa D. S., Rose, Peter G., Olawaiye, Alexander, Edwards, Robert P., Uger, Robert A., Lin, Gloria H. Y., Mahdi, Haider
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356752/ https://www.ncbi.nlm.nih.gov/pubmed/37468567 http://dx.doi.org/10.1038/s41698-023-00418-4

Ejemplares similares

Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
por: Yang, Hongcheng, et al.
Publicado: (2019)

Expression and Prognostic Significance of CD47–SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer
por: Sugimura-Nagata, Akane, et al.
Publicado: (2021)

RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors
por: Roulston, Anne, et al.
Publicado: (2022)

Registered report: The CD47-signal regulated protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
por: Chroscinski, Denise, et al.
Publicado: (2015)

Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
por: Horrigan, Stephen K
Publicado: (2017)

“Marker of Self” CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumors
por: Sosale, Nisha G, et al.
Publicado: (2016)

Vitamin E succinate exerts anti-tumour effects on human cervical cancer cells via the CD47-SIRPɑ pathway both in vivo and in vitro
por: Huang, Xiaoli, et al.
Publicado: (2021)

PARP1-Erk synergism in proliferating cells
por: Visochek, Leonid, et al.
Publicado: (2018)

High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma
por: Tao, Ke, et al.
Publicado: (2022)

Síndrome de Insuficiencia Respiratoria Progresiva del Adulto (SIRPA) : Revisión bibliográfica y presentación de casos clínicos (Centro Médico Nacional de Veracuz) / :
por: Montiel Pacheco, Antonio Guillermo
Publicado: (1990)

Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer
por: Chen, Xiu-Xiu, et al.
Publicado: (2015)

Retracted: High SIRPA Expression Predicts Poor Prognosis and Correlates with Immune Infiltrates in Patients with Esophageal Carcinoma
por: Healthcare Engineering, Journal of
Publicado: (2023)

PARP-1 inhibitor monotherapy and combination therapy in a preclinical mouse model of Brca2 mutant breast cancer
por: Hay, T, et al.
Publicado: (2008)

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers
por: Teyssonneau, Diego, et al.
Publicado: (2022)

A PARP1-ERK2 synergism is required for the induction of LTP
por: Visochek, L., et al.
Publicado: (2016)

Signal-induced PARP1-Erk synergism mediates IEG expression
por: Cohen-Armon, Malka, et al.
Publicado: (2019)

Comparative Analysis of piggyBac, CRISPR/Cas9 and TALEN Mediated BAC Transgenesis in the Zygote for the Generation of Humanized SIRPA Rats
por: Jung, Chris J., et al.
Publicado: (2016)

Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
por: Chen, Zheling, et al.
Publicado: (2021)

PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy
por: Bian, X, et al.
Publicado: (2018)

PARP inhibition in UV-associated angiosarcoma preclinical models
por: Weidema, Marije E., et al.
Publicado: (2021)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
por: Fang, Douglas D., et al.
Publicado: (2021)

CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials
por: Zhang, Zhongkun, et al.
Publicado: (2021)

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022)

Alkannin-Induced Oxidative DNA Damage Synergizes With PARP Inhibition to Cause Cancer-Specific Cytotoxicity
por: Chang, Mingxin, et al.
Publicado: (2020)

MBRS-19. SYNERGISM OF HDAC AND PARP INHIBITORS IN MYC-DRIVEN GROUP 3 MEDULLOBLASTOMA CELLS
por: Vollmer, Johanna, et al.
Publicado: (2020)

PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth
por: Bhattacharjee, Sayani, et al.
Publicado: (2022)

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models
por: Pignochino, Ymera, et al.
Publicado: (2017)

Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4(+) BTLA(+) T Cells in Tumor Microenvironment of Mycosis Fungoides
por: Jiang, Tony T., et al.
Publicado: (2021)

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016)

Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models
por: Bai, Lijuan, et al.
Publicado: (2023)

A PARP1-Erk2 synergism is required for stimulation-induced expression of immediate early genes
por: Cohen-Armon, M.
Publicado: (2016)

VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases
por: Ekstrom, Thomas L., et al.
Publicado: (2021)

Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma
por: Zhang, Xi, et al.
Publicado: (2022)

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
por: Virtanen, Verneri, et al.
Publicado: (2019)

Privileged Scaffolds for Potent and Specific Inhibitors of Mono-ADP-Ribosylating PARPs
por: Nizi, Maria Giulia, et al.
Publicado: (2023)

Hepatosplenic T-cell lymphoma in a 47-year-old Crohn’s disease patient on thiopurine monotherapy
por: van de Meeberg, Maartje M, et al.
Publicado: (2016)

Overexpression of tripartite motif-containing 47 (TRIM47) confers sensitivity to PARP inhibition via ubiquitylation of BRCA1 in triple negative breast cancer cells
por: Liu, Fengen, et al.
Publicado: (2023)

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
por: Ke, Hang, et al.
Publicado: (2023)

Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells
por: Uddin, Md. Hafiz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g6o69l041kldqug7moetarlgsm